Finance

Lists
Why is PMN down 5,53%?
Dive Deeper
PMN:NASDAQ
Promis Neurosciences Inc
3,76 US$
-5,53%
(-0,22) 1D
3,69 US$
-1,86% (-0,070)
After hours
Closed: 11 ნოე, 16:00:00 GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for PMN...
Open
4,09 US$
High
4,22 US$
Low
3,69 US$
Mkt. cap
33,72 მლნ.
Avg. vol.
281,54 ათ.
Volume
0,00
52-wk high
27,40 US$
52-wk low
2,78 US$
EPS
-12,61 US$
Beta
-0,15
Shares outstanding
8,97 მლნ.
No. of employees
11
Open
4,09 US$
High
4,22 US$
Low
3,69 US$
Mkt. cap
33,72 მლნ.
Avg. vol.
281,54 ათ.
Volume
0,00
52-wk high
27,40 US$
52-wk low
2,78 US$
EPS
-12,61 US$
Beta
-0,15
Shares outstanding
8,97 მლნ.
No. of employees
11
News stories
From web sources and news partners
About Promis Neurosciences Inc
CEO-
Employees11
Founded2005
Headquartersმისისოგა, ონტარიო, კანადა
SectorHealth Care
Industry-
Websitepromisneurosciences.com
Analyst ratings
Based on 5 analysts giving stock ratings to PMN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for PMN in the last 3 months.
Highest
Current 3,76 US$
100,00 US$ (+2 559,57%)
Average
40,20 US$ (+969,15%)
Lowest
15,00 US$ (+298,94%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
18,00 US$
+378,7%
11/09/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
15,00 US$
+298,9%
11/02/2026
Jason McCarthy
Maxim Group
Buy
Maintained
35,00 US$
+830,9%
08/14/2026
Eddie Hickman
Guggenheim
Buy
Reiterated
100,00 US$
+2 559,6%
08/14/2026
Keay Nakae
Chardan Capital
Buy
Maintained
33,00 US$
+777,7%
08/13/2026
Unknown Analyst
Guggenheim
Buy
Maintained
35,00 US$
+830,9%
07/14/2026
Pete Stavropoulos
Cantor Fitzgerald
Buy
Initiated
39,75 US$
+957,2%
06/29/2026
Unknown Analyst
Brookline Capital Markets
Buy
Initiated
40,00 US$
+963,8%
05/20/2026
Previous reportsAll values in CAD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
-
Cost of goods sold
9,80 მლნ.
9,37 მლნ.
-
9,52 მლნ.
Cost of revenue
9,80 მლნ.
9,37 მლნ.
-
9,52 მლნ.
Research and development expenses
-
-
6,97 მლნ.
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1,95 მლნ.
1,40 მლნ.
1,67 მლნ.
2,74 მლნ.
Operating expense
1,95 მლნ.
1,40 მლნ.
8,64 მლნ.
2,74 მლნ.
Total operating expenses
11,75 მლნ.
10,77 მლნ.
8,64 მლნ.
12,27 მლნ.
Operating income
-11,75 მლნ.
-10,77 მლნ.
-8,64 მლნ.
-12,27 მლნ.
Other non operating income
170,31 ათ.
98,03 ათ.
400,52 ათ.
536,74 ათ.
EBT including unusual items
-11,58 მლნ.
-10,67 მლნ.
-8,24 მლნ.
-11,73 მლნ.
EBT excluding unusual items
-11,58 მლნ.
-10,67 მლნ.
-8,24 მლნ.
-11,73 მლნ.
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-11,58 მლნ.
-10,67 მლნ.
-8,24 მლნ.
-11,73 მლნ.
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-
-
-
-
Net interest expenses
-
-
-
-
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები